Clinical implications of glucocorticoid metabolism by 11β-hydroxysteroid dehydrogenases in target tissues

European Journal of Endocrinology

Volumn 144, Issue 2, 2001, Pages 87-97

  Quinkler, M ^a   Oelkers, W ^a   Diederich, S ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; CORTICOTROPIN; CORTISONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOSE; HYDROCORTISONE; ISOENZYME; MINERALOCORTICOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DESCENDING COLON; DIABETES MELLITUS; ECTOPIC CORTICOTROPIN PRODUCTION; ENZYME DEFECT; ENZYME MECHANISM; ENZYME REGULATION; ESSENTIAL HYPERTENSION; GENE EXPRESSION; GENE FUNCTION; GLUCOSE HOMEOSTASIS; GLYCYRRHIZA; HUMAN; HUMAN CELL; ILEUM; KIDNEY; LIVER; METABOLISM; MOUSE; NONHUMAN; OBESITY; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND; STEROID METABOLISM; TARGET ORGAN; TISSUE DISTRIBUTION;

EID: 0035114538     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1440087     Document Type: Review

References (122)

1. Tissue localization of 11β-Hydroxysteroid dehydrogenase and its relationship to the glucocorticoid receptor
2. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids
3. Immunolocalization of renal mineralocorticoid receptors with an antiserum against a peptide deduced from the complementary deoxyribonucleic acid sequence
4. The ontogeny of 11β-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development
5. Glucocorticoid receptor mineralocorticoid receptors, 11β-hydroxysteroid dehydrogenase-1 and 2-expression in rat brain and kidney: In situ studies
6. General overview of mineralocorticoid hormone action
7. Cloning of human mineralocortoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor
8. Localisation of 11β-hydroxysteroid dehydrogenase - Tissue specific protector of the mineralocorticoid receptor
9. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated
10. Pharmacology of 11β-hydroxysteroid dehydrogenase
11. A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man
12. How can aldosterone act as a mineralocoticoid?
13. Chemical and biological factors in the activity of adrenocortical steroids
14. Mineralocorticoid selectivity: Molecular and cellular aspects
15. Evidence for the secretion of an antimineralocorticoid in congenital adrenal hyperplasia
16. Progesterone binding to mineralocorticoid receptors: In vitro and in vivo studies
17. Structure-activity relationships for agonistic and antagonistic mineralocorticoids
18. Effect of cortisone and pituitary adrenocorticotrophic hormone (ACTH) in rheumatic diseases
19. Hydrocortisone and cortisone injected into arthritic joints. Comparative effects of and use of hydrocorticome as a local antiarthritic agent
20. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme
21. The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization
22. Detection of human 11β-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts
23. 11β-hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of rat hepatocytes. Effect of physicochemical and hormonal manipulations
24. 11β-Hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: A model system for the study of hepatitic glucocorticoid metabolism
25. Liver-type' 11β-hydroxysteroid dehydrogenase cDNA encodes reductase but not dehydrogenase activity in intact mammalian COS-7 cells
26. The 11β-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralcorticoid action - Medical and physiological aspects of the 11β-hydroxysteroid dehydrogenase system
27. Effect of growth hormone, insulin and dexamethasone on 11β-hydroxysteroid dehydrogenase activity on a primary culture of rat hepatocytes
28. Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues
29. 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuates glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress
30. The 11β-hydroxysteroid dehydrogenase system a determinant of glucocoticoid and mineralocorticoid action - Role of type-1 11β-hydroxysteroid dehydrogenase in detoxification process
31. The protective role of 11β-hydroxysteroid dehydrogenase/carbonyl reductase against tobacco-smoke related lung cancer
32. Interindividual variability in the expression and NNK carbonyl reductase activity of 11β-hydroxysteroid dehydrogenase 1 in human lung
33. Does central obesity reflect 'Cushing's disease of the omentum'?
34. Differentiation of adipose stromal cells: The roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase
35. Expression of 11β-hydroxysteroid dehydrogenase during decidualization of human endometrial stromal cells
36. Interconversion of cortisol and cortisone in baboon trophoblast and decidua cells in culture
37. Regulation of 11β-hydroxysteroid dehydrogenase activity in the baboon placenta by estrogen
38. Correlation of surfactant phosphatidylcholine synthesis and 11β-hydroxysteroid dehydrogenase in the fetal lung
39. Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney placenta
40. Colocalization of 11β-hydroxysteroid dehydrogenase epithelia
41. Immunodetection of 11β-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: Evidence for nuclear localization
42. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid
43. Vascular localization of the 11β-hydroxysteroid dehydrogenase type II enzyme
44. Glucocorticoids and blood pressure: A role for the cortisol/cortisone shuttle in the control of vascular tone in man
45. Localization of 11β-hydroxysteroid dehydrogenase type I in human epithelial tissues
46. Placental 11β-hydroxysteroid dehydrogenase: A key regulator of fetal glucocorticoid exposure
47. Type 2 11β-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: Its relationship to birth weight and putative role in fetal adrenal steroidogenesis
48. Reciprocal cortisol-cortisone conversion sin the total tissue and subcellular fractions of foetal and adult guinea pig liver
49. Purification of 11β-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique
50. Cloning and production of antisera to human placental 11β-hydroxysteroid dehydrogenase type 2
51. Metabolism of dexamethasone in the human kidney: Nicotinamide adenine dinucleotide-dependent 11β-reduction
52. 11β-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human placenta
53. 11β-hydroxysteroid dehydrogenase type 2 in human lung: Possible regulator of mineralocorticoid action
54. Hybridization histochemical localization of 11β-hydroxysteroid dehydrogenase type 2 in rat brain
55. Impaired renal 11β-oxidation of 9α-fluorcortisol: An explanation for its mineralocorticoid potency
56. The metabolism of 9α-fluorinated steroids in the human kidney
57. Oxoreductase and dehydrogenase activities of the human and rat 11β-hydroxysteroid dehydrogenase type 2 enzymes
58. 11β-Hydroxysteroid dehydrogenase: Implications for clinical medicine
59. Inactivation of 11β-hydroxysteroid dehydrogenase type 2 by gene targeting in mice
60. Tissue-specific modulation of glucocorticoid action by the 11β-hydroxysteroid dehydrogenase
61. Carbenoxolone increases hepatic insulin sensitivity in man: A novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation
62. Cortisone reductase deficiency: Evidence for a new inborn error in metabolism of adrenal steroids
63. Increased metabolic clearance of cortisol in corticosteroid 11-reductase deficiency
64. A new defect in the peripheral conversion of cortisone to cortisol
65. Apparent cortisone reductase deficiency: A unique form of hypercortisolism
66. Apparent cortisone reductase deficiency: A functional defect in 11β-hydroxysteroid dehydrogenase type 1
67. Failure of cortisone acetate treatment in congenital adrenal hyperplasi because of defective 11β-hydroxysteroid dehydrogenase reductase activity
68. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11β-hydroxysteroid dehydrogenase
69. Interactions between oestradiol and glucocorticoid regulatory effects on liver-specific glucocorticoid-inducible genes: Possible evidence for a role of hepatic 11β-hydroxysteroid dehydrogenase type 1
70. Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: Relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition
71. Modulation of 11β-hydroxysteroid dehydrogenase isoenzymes by growth hormone and insulin-like growth factor: In vivo and in vitro studies
72. Clinical aspects of growth hormone deficiency in adults
73. Sexual dimorphism in 11β-hydroxysteroid dehydrogenase activity and its relation to fat distribution and insulin sensitivity: A study in hypopituitary subjects
74. Obesity and gender difference cortisol secretion and metabolism in man
75. Cortisol metabolism in human obesity: Impaired cortisone to cortisol conversion in subjects with central adiposity
76. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension
77. Unusual steroids exertion in a child with low renin hyprtension
78. A syndrome of apparent mineralocorticois excess associated with defects in the peripheral metabolism of cortisol
79. Congenital and acquired syndromes of apparent mineralocorticoid excess
80. Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase
81. A new compound heterozygous mutation inthe 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess
82. The role of the 11β-hydroxysteroid dehydrogenase type 2 in human hypertension
83. 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoids excess
84. Liddle's syndrome: Heritable human hypertension caused by mutations in the subunit of the epithelial sodium channel
85. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension
86. 11β-hydroxysteroid dehydrogenase
87. Cure of apparent mineralocorticoid excess by kidney transplantation
88. A new polymorphic restriction site in the human 11β-hydroxysteroid dehydrogenase type 2 gene
89. Structure analysis and evaluation of the 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD 2) gene in human essential hypertension
90. Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated essential hypertension
91. Sodium status, corticosteroid metabolism and blood pressure in normal human subjects and in a patients with abnormal salt appetite
92. The activities of 5β-reductase and 11β-hydroxysteroid dehydrogenase in essential hypertension
93. Placental 11β-hydroxysteroid dehydrogenase and the programming of hypertension
94. Placental 11β-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic pregnancies
95. Glucocorticoid exposure in utero: New model for adult hypertension
96. Dysfunction of placental glucocorticoid barrier: Link between fetal environment and adult hypertension?
97. Inhibition of 11β-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring
98. Variation in placental type 2 11β-hydroxysteroid dehydrogenase activity is not related to birth weight or placental weight
99. Human skin as target for aldosterone: Coexpression of mineralocorticoid receptors and 11β-hydroxysteroid dehydrogenase
100. Organ-specific actions of 11β-hydroxysteroid dehydrogenase in humans: Implications for the pathophysiology of hypertension
101. Aldosterone biosynthesis in the rat brain
102. Progesterone metabolism in the human kidney and inhibition of 11β-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites
103. Mineralocorticoids and mineralocorticoid receptors in mononuclear leukocytes in patients with pregnancy-induced hypertension
104. Reninaldosterone relationships in pregnancy-induced hypertension
105. Plasma renin activity and aldosterone serum concentration are decreased in severe preeclampsia but not in the HELLP-syndrome
106. Longitudinal study of the study of the renin-angiotensin-aldosterone system in hypertensive pregnant women: Deviations related to the development of superimposed preeclampsia
107. Alteration of the activity of the 11β-hydroxysteroid dehydrogenase in patients with pre-eclampsia
108. A liquorice extract with deoxycortone-like action
109. Affinity of liquorice derivatives for mineralocorticoid and glucocorticoid receptors
110. Licorice inhibits corticosteroid 11β-dehydrogenase of rat kidney and liver: In vivo and in vitro studies
111. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney
112. Effects of prolonged ingestion of graded doses of licorice by healthy volunteers
113. Licorice raises urinary cortisol in man
114. The influence of glycyrrhetic acid on plasma cortisol and cortisone in healthy young volunteers
115. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age
116. Pathogenesis of hypokalemic alkalosis in Cushing's syndrome
117. Diagnosis and management of ACTH-dependent Cushing's syndrome: Comparison of the features in ectopic and pituitary ACTH production
118. 20-Dihydroisomers of corsitol and cortisone in human urine: Excretion rates under different physiological conditions
119. Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome
120. Human kidney 11β-hydroxysteroid dehydrogenase: Regulation by adrenocorticortitropin?
121. Cortisol inactivation overload: A mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome
122. In the search for specific inhibitions of human 11β-hydroxysteroid dehydrogenase (11β-HSDs): Chenodeoxycholic acid selectivity inhibits 11β-HSD-I